Drug intelligence / Profile preview

omega 3 + nigella sativa oil + quinine

Development stage
Preclinical
Lead developer
TriNutra
Modality
Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
Administration
Oral
01

Overview

This is a combination product containing three active ingredients: - **Omega-3 fatty acids** (commonly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]), which are polyunsaturated fats known for their anti-inflammatory effects and benefits in cardiovascular health, metabolic syndrome, and cognitive function. - **Nigella sativa oil** (black seed or black cumin seed oil), standardized to thymoquinone content. Thymoquinone is the main bioactive component with potent antioxidant and anti-inflammatory properties. Nigella sativa has been studied for its potential roles in modulating immune response, reducing inflammation, improving insulin sensitivity, supporting gut health, and promoting the browning of white adipose tissue to counteract obesity-related metabolic dysfunction[2][4][5][6]. - **Quinine**, an alkaloid traditionally used as an antimalarial agent but also possessing muscle relaxant and mild analgesic properties. The combination of omega-3 fatty acids with Nigella sativa oil has demonstrated synergistic effects in preclinical studies—reducing obesity-induced oxidative stress and inflammation, improving insulin resistance markers by enhancing mitochondrial function and promoting the conversion of unhealthy white fat to metabolically active beige fat[2][4][5][6]. Clinical data suggest additional benefits on immune modulation (e.g., fewer upper respiratory tract complaints) when combining these two oils[3]. The addition of quinine is less common in dietary supplements; its inclusion may be intended for further anti-inflammatory or other pharmacological effects.

Other names
omega-3 + black seed oil + quinineomega-3 fatty acids + nigella sativa oil + quininefish oil + black cumin seed oil + quinine
02

Targets

PPARG (Peroxisome proliferator-activated receptor gamma)PRKAA1 (AMP-activated protein kinase alpha catalytic subunit isoform alpha-1)

Beyond the preview

Go deeper on omega 3 + nigella sativa oil + quinine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on omega 3 + nigella sativa oil + quinine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call